PLCB4

Across TCGA pan-cancer cohorts, PLCB4 Mutation is linked to patient survival in 12 of 34 cancer types, making it a survival-associated PLCB4 data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher PLCB4 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated PLCB4 expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.

UCEC, UCS, and ESCA are the cancer types where PLCB4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	II,III,IV	0.945	0.425	.004	32	view →
UCS	OS	Median	All	0.007	0.689	<.001	24	view →
ESCA	OS	Median	II,III,IV	0.117	0.687	<.001	18	view →
UVM	OS	Median	All	0.104	0.834	<.001	15	view →
BRCA	OS	Median	II,III,IV	0.854	0.958	.005	13	view →
PRAD	OS	Median	All	0.770	0.990	<.001	8	view →
SCLC	OS	Median	All	0.082	0.822	<.001	6	view →
ACC	OS	Median	All	0.118	0.624	.038	6	view →
LUSC	DFS	Median	II,III,IV	0.198	0.673	.027	3	view →
BLCA	OS	Median	III,IV	1.000	0.670	.036	2	view →
LUAD	OS	Median	III,IV	1.000	0.483	.037	2	view →
SKCM	DFS	Median	II,III,IV	0.785	0.644	.039	1	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 12 lineages.

PLCB4–UCEC (DFS)

Open the UCEC breakdown →